



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 401/06, 407/14, A61K 31/44	A1	(11) International Publication Number: WO 99/50262 (43) International Publication Date: 7 October 1999 (07.10.99)
(21) International Application Number: PCT/EP99/02045 (22) International Filing Date: 24 March 1999 (24.03.99) (30) Priority Data: 98201020.9 1 April 1998 (01.04.98) EP (71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). (72) Inventors; and (75) Inventors/Applicants (for US only): FREYNE, Eddy, Jean, Edgard [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). DIELS, Gaston, Stanislas, Marcella [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). MATE-SANZ-BALLESTEROS, Maria Encarnacion [ES/ES]; Janssen-Cilag S.A., Edificio Johnson & Johnson, Paseo de las Doce Estrellas, 5-7, 5° planta, Campo de las Maciones, E-28042 Madrid (ES). DIAZ-MARTINEZ, Adolfo [ES/ES]; Janssen-Cilag S.A., Edificio Johnson & Johnson, Paseo de las Doce Estrellas, 5-7, 5° planta, Campo de las Maciones, E-28042 Madrid (ES).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.
(54) Title: PDE IV INHIBITING PYRIDINE DERIVATIVES (I) (57) Abstract The present invention concerns pyridine derivatives having formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein L is hydrogen; C₁₋₆alkyl; C₁₋₆alkyl carbonyl; C₁₋₆alkyloxycarbonyl; substituted C₁₋₆alkyl; C₃₋₆alkenyl; substituted C₃₋₆alkenyl; piperidyl; substituted piperidyl; C₁₋₆alkylsulfonyl or arylsulfonyl; -A-B- is -CR⁴-CR⁵- or -CHR⁴-CHR⁵-; D is O or NR⁶; R¹ is a hydrogen or C₁₋₆alkyl; R² is hydrogen; halo; C₁₋₆alkyl; trifluoromethyl; C₃₋₆cycloalkyl; carboxyl; C₁₋₆alkyl oxycarbonyl; C₃₋₆cycloalkylaminocarbonyl; aryl; HET⁷; or substituted C₁₋₆alkyl; or R² is O-R⁹ or NH-R¹⁰; R³ is hydrogen, halo, hydroxy, C₁₋₆alkyl or C₁₋₆alkyloxy; or R² and R¹, or R² and R³ taken together may form a bivalent radical; Q is disubstituted pyridine; R⁷ and R⁸ each independently are hydrogen; C₁₋₆alkyl; difluoromethyl; trifluoromethyl; C₃₋₆cyclo alkyl; a saturated 5-, 6- or 7-membered heterocycle containing one or two heteroatoms selected from oxygen, sulfur or nitrogen; indanyl; 6,7-dihydro-5H-cyclopentapyridyl; bicyclo[2.2.1]-2-heptenyl; bicyclo[2.2.1]heptanyl; C₁₋₆alkylsulfonyl; arylsulfonyl; or substituted C₁₋₁₀alkyl; having PDE IV and cytokine inhibiting activity. The invention also relates to processes for preparing the compounds of formula (I), pharmaceutical compositions thereof and their use as a medicament.		